RedHill buys Rebyota and Clenpiq rights from Ferring

RedHill Biopharma said Sept. 1 it acquired commercialization rights to Ferring’s Rebyota and Clenpiq, adding two FDA-approved GI drugs that generated about $37.5 million in 2025 net sales. The move follows RedHill’s Talicia divestiture and gives the company a larger, more liquid commercial GI business.

Why it matters: - RedHill is reshaping its GI portfolio around two established revenue-generating products instead of a smaller mixed commercial base. - The company says the transaction, paired with the Talicia divestiture, leaves it with a stronger liquidity position and room for more acquisitions. - Rebyota and Clenpiq together generated about $37.5 million in 2025 net sales, giving RedHill a more material commercial platform.

What happened: - RedHill Biopharma announced Sept. 1 that it acquired exclusive commercialization rights to Ferring Pharmaceuticals' Rebyota and Clenpiq. - RedHill got an exclusive global commercialization license for Rebyota and an exclusive U.S. commercialization license for Clenpiq. - RedHill paid $12 million upfront and may owe tiered royalties on net sales and potential milestones. - The $12 million payment is fully funded by RedHill's previously announced $18 million Talicia divestiture. - Ferring retains its Rebyota manufacturing facilities and will continue to supply Rebyota during the term of the agreement.

The details: - Rebyota is a single-dose, FDA-approved microbiota-based therapy for preventing recurrent Clostridioides difficile infection in adults 18 and older after antibiotic treatment. - Rebyota was FDA-approved in 2022 and Health Canada-approved in 2025. - Rebyota generated about $16.9 million in U.S. net sales in 2025. - RedHill said Rebyota has more than 600 active accounts and broad payer coverage. - Rebyota's administration does not require fasting, bowel prep or an extended treatment timeline. - RedHill said Rebyota has shown more than a 70% success rate at preventing recurrent infection. - Rebyota carries Breakthrough Therapy and Orphan Drug designations, with protections and other patent rights that could run to 2036. - RedHill said Rebyota's existing approvals could support additional territory expansions. - Clenpiq is a ready-to-drink, low-volume bowel preparation in the U.S. market. - Clenpiq generated $20.6 million in U.S. net sales in 2025 with minimal promotion. - RedHill said Clenpiq has broad commercial and government payer coverage, including more than 108 million lives with unrestricted commercial coverage and 23 million Medicare Part D lives with unrestricted access. - The company also said 57 million commercial lives have preferred positioning, and 12 million Medicare Part D lives have preferred positioning. - RedHill said the two assets create a stronger commercial growth engine in the U.S. and other territories. - The company was advised by Morningstar Law Group and Greenberg Traurig LLP.

Between the lines: - This is a pivot toward mature GI brands that already have sales, coverage and established prescriber bases. - RedHill is signaling that it wants lower-risk commercial assets that can produce cash rather than depend mainly on pipeline development. - Ferring's continued manufacturing role reduces operational disruption while RedHill takes over commercialization. - The deal also suggests RedHill sees expansion value beyond the U.S., especially for Rebyota.

What's next: - RedHill expects Rebyota and Clenpiq to generate positive cash contribution. - The company said it will use its commercial team and development capabilities to support further growth. - RedHill is looking at additional acquisition opportunities for complementary revenue-generating products. - Future expansion could include more territories for Rebyota if regulatory approvals are secured.

The bottom line: - RedHill is trading a narrower GI footprint for a larger, better-funded commercial business with two products that already have meaningful market traction.